GGHC
RCUS icon

Gilder Gagnon Howe & Co’s Arcus Biosciences RCUS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,016
Closed -$189K – 252
2025
Q1 		$189K Sell
24,016
-95,034
-80% -$1.1M ﹤0.01% 229
2024
Q4 		$1.77M Sell
119,050
-7,336
-6% -$120K 0.02% 191
2024
Q3 		$1.93M Sell
126,386
-11,641
-8% -$184K 0.02% 186
2024
Q2 		$2.1M Sell
138,027
-36,628
-21% -$591K 0.03% 176
2024
Q1 		$3.3M Buy
174,655
+35,485
+25% +$614K 0.04% 168
2023
Q4 		$2.66M Sell
139,170
-99,362
-42% -$1.59M 0.04% 169
2023
Q3 		$4.28M Sell
238,532
-2,657
-1% -$53.4K 0.07% 153
2023
Q2 		$4.9M Buy
241,189
+13,078
+6% +$249K 0.07% 157
2023
Q1 		$4.16M Sell
228,111
-10,728
-4% -$205K 0.07% 142
2022
Q4 		$4.94M Sell
238,839
-2,388
-1% -$65.7K 0.09% 134
2022
Q3 		$6.31M Buy
241,227
+19,145
+9% +$506K 0.11% 122
2022
Q2 		$5.63M Sell
222,082
-69,198
-24% -$1.69M 0.1% 130
2022
Q1 		$9.19M Sell
291,280
-1,388
-0.5% -$46.5K 0.09% 145
2021
Q4 		$11.8M Buy
292,668
+1,665
+0.6% +$64.6K 0.07% 165
2021
Q3 		$10.1M Sell
291,003
-6,085
-2% -$189K 0.05% 197
2021
Q2 		$8.16M Sell
297,088
-7,124
-2% -$203K 0.04% 227
2021
Q1 		$8.54M Sell
304,212
-11,599
-4% -$404K 0.05% 212
2020
Q4 		$8.2M Sell
315,811
-554,823
-64% -$13.4M 0.04% 194
2020
Q3 		$14.9M Buy
870,634
+65,560
+8% +$1.46M 0.09% 150
2020
Q2 		$19.9M Buy
805,074
+784,944
+3,899% +$21.2M 0.16% 119
2020
Q1 		$279K Sell
20,130
-1,226
-6% -$15.2K ﹤0.01% 233
2019
Q4 		$216K Buy
21,356
+441
+2% +$3.71K ﹤0.01% 263
2019
Q3 		$190K Buy
20,915
+472
+2% +$3.79K ﹤0.01% 262
2019
Q2 		$163K Buy
+20,443
New +$205K ﹤0.01% 273

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Gilder Gagnon Howe & Co's RCUS Position: Q2 2025 in Review

Gilder Gagnon Howe & Co sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 24,016 shares — an estimated $189K sold.

Gilder Gagnon Howe & Co first reported a position in RCUS in Q2 2019 and held it in 24 quarters. The position peaked at $19.9M in Q2 2020. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Gilder Gagnon Howe & Co reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 24,016 Arcus Biosciences shares in Q2 2025, an estimated $189K.
  • Gilder Gagnon Howe & Co first reported a position in Arcus Biosciences in Q2 2019 and held it in 24 quarters.
  • Gilder Gagnon Howe & Co's Arcus Biosciences position peaked at $19.9M in Q2 2020.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2025, filed 14 Aug 2025.